PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0871189|psychotic symptoms |
| Sentences | 43 |
| PubMedID- 20932348 | In these studies, the majority of participants were also in their early twenties and in the early phase of schizophrenia with acute psychotic symptoms. |
| PubMedID- 21285142 | Objective: because reduction of psychotic symptoms in schizophrenia does not result in adequate community functioning, efforts have shifted to other areas, such as cognitive impairment. |
| PubMedID- 26483630 | schizophrenia is commonly associated with psychotic symptoms; however, patients also experience negative symptoms such as lack of motivation and alogia, as well as cognitive difficulties such as attention problems and memory deficits. |
| PubMedID- 25539511 | Surprisingly, there is strong evidence that thc exacerbates psychotic symptoms in patients with schizophrenia (d’souza et al., 2005, 2009; mason et al., 2009; machielsen et al., 2010). |
| PubMedID- 22949284 | Lifetime prevalence and correlates of schizophrenia and disorders with psychotic symptoms in the general population of izmir, turkey. |
| PubMedID- 26265348 | A third report describes a notable deterioration in psychotic symptoms in a patient with schizophrenia during the six months of rifampicin therapy ; no data on clozapine levels were available, but the deterioration in symptoms persisted despite an increase in the dose of clozapine from 300 mg to 550 mg/day. |
| PubMedID- 25140221 | psychotic symptoms of amphetamines and schizophrenia are similar as well. |
| PubMedID- 19350535 | These findings suggest that genetic factors significantly contribute to the age of onset of psychotic symptoms in individuals with schizophrenia and that sex influences this trait as well. |
| PubMedID- 25093771 | The response of psychotic symptoms in a patient with resistant schizophrenia under treatment of high-dose risperidone long-acting injection. |
| PubMedID- 23205697 | Past research has emphasized the association between stress and the manifestation of psychotic symptoms in schizophrenia, yet relatively little is known about how environmental stressors affect cognitive processes in the illness. |
| PubMedID- 23394123 | On the other hand, there is evidence to suggest that disease progression does not occur as a consequence of relapse: 1) it has been reported that patients’ symptoms rapidly return to baseline with resumption of antipsychotic medication shortly after recurrence of psychotic symptoms; 2) in patients with relatively refractory schizophrenia who were exposed to placebo treatment for at least 6 weeks and experienced symptom worsening, it was found that, given a sufficiently lengthy recovery period, symptom levels returned to those of baseline; 3) response trajectory analyses in early psychosis suggest that, while some patients respond poorly initially, response is generally characterised by amelioration; 4) the clinical and neurobiological evidence for neurotoxicity of psychosis has been reviewed and found wanting; 5. finally, a recent paper challenges the concept of schizophrenia as a progressive brain disease, arguing the following: a) while longitudinal studies report a poor outcome in approximately 25% of patients, few of them describe incremental deterioration that would characterize neurodegenerative disorders; b) while some neuro-imaging studies report brain tissue volumes decreasing over time, this could be attributed to the effects of antipsychotic medication, substance abuse, effects of lifestyle or elevated glucocorticoid levels associated with chronic stress; c) cognitive functioning does not appear to deteriorate over time; and d) the deterioration that occurs in some patients could reflect poor access, or adherence, to treatment, the effects of concomitant conditions, and social and financial impoverishment. |
| PubMedID- 23736279 | Objectives: we reviewed reported cases which have suggested that aripiprazole can worsen psychotic symptoms in schizophrenia and evaluated each regarding quality of the causal relationship. |
| PubMedID- 23020603 | The aim of this study was to examine the psychometric properties of the french version of the psyrats in a sample of patients suffering from schizophrenia spectrum disorders with persistent psychotic symptoms. |
| PubMedID- 22925596 | Referrals are only excluded if they have: high current risk of suicide (current suicide plans and intent to kill themselves); current psychotic symptoms (due to schizophrenia or bipolar affective disorder or severe depression with psychotic features); current substance abuse/misuse (severe dependency on alcohol, illicit drugs or tranquilisers) or cognitive impairment that impedes the use of a computer. |
| PubMedID- 22816371 | Conclusion: we observed significant improvements of medium effect sizes in psychotic symptoms of patients with schizophrenia spectrum disorders within a naturalistic clinical setting, especially for fep patients. |
| PubMedID- 26030357 | Furthermore, alexithymia does not appear to be related to psychotic symptoms in patients with schizophrenia over time . |
| PubMedID- 21784619 | The similarity between psychotic symptoms in patients with schizophrenia such as hallucinations and delusions and those caused by administration of methamphetamine has been accepted. |
| PubMedID- 21533181 | Furthermore, decreased fa at the left fornix and increased ad at right cingulum correlated with greater severity of psychotic symptoms in patients with schizophrenia, suggesting that disruption of white matter integrity may contribute towards the neural basis of clinical symptomatology. |
| PubMedID- 25970596 | In addition, some non-steroidal anti-inflammatory drugs are effective as adjuvant therapy in treating psychotic symptoms in patients with schizophrenia . |
| PubMedID- 25137629 | Positive allosteric modulators (pams) of the m4 muscarinic acetylcholine receptor (machr) represent a novel approach for the treatment of psychotic symptoms associated with schizophrenia and other neuropsychiatric disorders. |
| PubMedID- 25468627 | It has been suggested that data on positive and negative psychotic symptoms in patients with schizophrenia as assessed using different scales may be combined. |
| PubMedID- 20540956 | psychotic symptoms in schizophrenia patients encompass the difficulty to distinguish between the respective points of view of self and others. |
| PubMedID- 24179748 | psychotic symptoms in schizophrenia are related to disturbed self-recognition and to disturbed experience of agency. |
| PubMedID- 22363182 | Compared two distinct cognitive interventions in schizophrenia patients with medication-refractory psychotic symptoms: coping strategy enhancement (cse) and problem solving (ps) were compared after 5 weeks of treatment and at 6 months follow-up (19). |
| PubMedID- 24368428 | In addition to its negative impact on physical health, tobacco use has been associated with more excitement and agitation symptoms , greater severity of global psychopathology as measured by the clinical general impression (cgi) scale in patients with schizophrenia, although the effect size was small 6. |
| PubMedID- 23355781 | First, the depression and psychotic symptoms of the patients with schizophrenia in this study were moderately low. |
| PubMedID- 20840778 | While our analysis is limited by the lack of a subanalysis of clinical improvement versus appetite, it has been observed previously that clinical improvement of psychotic symptoms in patients with schizophrenia seems to coincide with increased food intake . |
| PubMedID- 24101897 | It has been suggested that estrogens are, in part, responsible for these sex differences, reducing the frequency of hospital admissions and diminishing the psychotic symptoms associated with schizophrenia (kendell et al., 1987; matevosyan, 2011). |
| PubMedID- 23672587 | Schizoaffective disorder, estimated to occur in less than 1% of the population, appears to represent a midpoint on the pathologic spectrum between bd i and schizophrenia with psychotic symptoms predominant and mood symptoms of mania and depression less evident (see figure 1) . |
| PubMedID- 25628048 | The disadvantaged socioeconomic status and psychotic symptoms present in patients with schizophrenia can also result in poor food choices.20 in the non-schizophrenic population, many with chronic illnesses, their treatments and even their medications usage can also contribute to the development of ckd: for example, comorbidity with diabetes mellitus, autoimmune diseases or nephritis; use of some nephrotoxic drugs21; or unhealthy lifestyles, obesity and the metabolic syndrome.22 therefore, unhealthy diets of low-fibre food, smoking habits, lack of exercise, disadvantaged socioeconomic status and metabolic syndrome may also contribute to the development of ckd among patients with schizophrenia. |
| PubMedID- 20478874 | Conclusions: cannabis use is associated with an adverse course of psychotic symptoms in schizophrenia, and vice versa, even after taking into account other clinical, substance use, and demographic variables. |
| PubMedID- 23450042 | Previous studies revealed that nmdar enhancing agent can alleviate psychotic symptoms of patients with schizophrenia . |
| PubMedID- 26121246 | Neat appearance was associated with psychotic symptoms in patients with schizophrenia . |
| PubMedID- 22867132 | The psychotic symptoms associated with schizophrenia are thought to be driven by increased dopamine neurotransmission in subcortical brain regions , but the underlying causes of this hyperdopaminergia are unknown. |
| PubMedID- 21042924 | Amfetamine increases synaptic release of dopamine in the mesolimbic system and is associated with increased positive psychotic symptoms in patients with schizophrenia . |
| PubMedID- 20504323 | Also, the dietary intake of pufa was negatively correlated with the severity of psychotic symptoms in patients with schizophrenia . |
| PubMedID- 24157506 | Although there is a post-marketing case report detailing exacerbated psychotic symptoms in a patient with schizophrenia being treated with varenicline for tobacco dependence , emerging clinical studies do not suggest that varenicline treatment worsens or exacerbates psychiatric symptoms. |
| PubMedID- 21550212 | Sgas efficacy on mania, extreme mood variability, irritability, aggression and disruptive behavior appears to be greater than for psychotic symptoms in schizophrenia: average nnt was 2-5, whereas for schizophrenia it varies between 3 for risperidone and 10 for olanzapine, quetiapine, and aripiprazole. |
| PubMedID- 23772215 | Interestingly, nmda receptor antagonists pcp and ketamine, previously shown to produce an elevation of psychotic symptoms in patients with schizophrenia, are among the drugs reported to result in sip (luby et al., 1959; lahti et al., 1995; gilmour et al., 2012). |
| PubMedID- 21509519 | Prior studies have suggested that variation in pdbetah, or genetic variants at dbetah, associate with differences in expression of psychotic symptoms in patients with schizophrenia and other idiopathic or drug-induced brain disorders, suggesting that dbh might be a genetic modifier of psychotic symptoms. |
| PubMedID- 23395840 | Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant: a case report. |
| PubMedID- 26086780 | Karolinska scales of personality, cognition and psychotic symptoms in patients with schizophrenia and healthy controls. |
| PubMedID- 23449968 | However, whereas antipsychotic drugs are widely used for the treatment of psychotic symptoms in patients with schizophrenia, typical (first-generation) antipsychotics often lead to severe motor side effects due to the blockade of dopamine d2 receptors . |
Page: 1